Quantcast

Latest Astellas Pharma Inc. Stories

2014-03-24 16:24:53

TOKYO, March 24, 2014 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) today announced that Astellas has obtained marketing approval of their oral androgen receptor signaling inhibitor, XTANDI(®) capsules 40mg (development code: MDV3100; generic name: enzalutamide) for the treatment of patients with castration-resistant prostate cancer in Japan. Astellas filed the application for approval in Japan in May 2013. XTANDI is a once-daily, oral androgen receptor signaling inhibitor that acts on...

2014-03-19 00:22:17

TOKYO, March 19, 2014 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503; President and CEO: Yoshihiko Hatanaka) and Daiichi Sankyo Company, Limited ("Daiichi Sankyo," President and CEO: Joji Nakayama) today announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. The collaboration enables each party to promote innovative new medicine research and development. This is the first time that a compound library...

2014-03-06 23:30:58

Deeper engagement with Association of Strategic Alliance Professionals reflects pharmaceutical leader’s focus on elevating the practice of alliance management within healthcare industry. Canton, Mass. (PRWEB) March 06, 2014 The Association of Strategic Alliance Professionals (ASAP), the world’s leading professional association dedicated to the practice of alliance management, today announced that leading pharmaceutical company Astellas Pharma Inc. has upgraded to Global Member....

2014-02-28 08:24:51

TOKYO, Feb. 28, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo:4503, "Astellas") announced today that the company has amended the License, Co-Development and Co-Promotion Agreement on isavuconazole under co-development with Basilea Pharmaceutica Ltd. ("Basilea"). Based on this amendment, the territories subject to the License Agreement have been changed to reflect that Astellas will be responsible for all regulatory filings and will exclusively commercialize and assume full...

2014-02-27 08:29:07

-- If isavuconazole is approved for invasive mucormycosis, QIDP status provides a five-year extension of market exclusivity -- NORTHBROOK, Ill., Feb. 27, 2014 /PRNewswire/ -- Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as...

2014-01-22 12:23:39

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Pharmerging Markets 2012-2016TechNavio's analysts forecast the Pharmerging market to grow at a CAGR of 12.44 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increase in healthcare spending. The Pharmerging market has also been witnessing an increase in partnerships among vendors. However, the price pressure could pose a challenge to the...

2014-01-06 04:21:45

In-license Vaccine Technology for Respiratory Syncytial Virus (RSV) from Mymetics TOKYO, ROCKVILLE, Md. and EPALINGES, Switzerland, Jan. 6, 2014 /PRNewswire/ -- Astellas Pharma Inc. (Astellas) and ClearPath Development Company (ClearPath) announced today a strategic partnership to form a portfolio of development companies focused on vaccines targeting infectious diseases. The partnership was established to support Astellas' goal of building a global vaccine franchise and launched...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related